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Product Liability and the Pill
Joyce Barrett*
T HE PILL IS BIG BUSINESS 1 to the eight United States manufacturers
of oral contraceptives, 2 and serious business to the estimated 8.5
million American women who each day swallow the innocuous-looking
little tablet. Grave doubts have been raised as to the safety of the Pill
by physicians, psychologists, medical researchers,3 and, finally, the Con-
gress of the United States.4 Some of these doubts are manifested in the
lawsuits (over 300)5 filed by Pill users (or their survivors) against Pill
manufacturers.
Searle-Where the Pill (and the Litigation)-Began
The lion's share of the oral contraceptive market belongs to G. D.
Searle & Co.-"Where the Pill Began." 6 The Pill did indeed begin at
Searle, in May of 1960, when it received permission from the Food and
Drug Administration to market Enovid.2 Litigation stemming from
alleged Pill-caused side effects began at Searle too. The first of such
cases to come to trial was Simonait v. Searle," which went to the jury
on theories of negligence and breach of implied warranty. Plaintiff
claimed that she had contracted thrombophlebitis (formation of blood
clots within the veins) as a result of taking the defendant's oral contra-
ceptive Enovid. She charged Searle with negligence in failing to warn
of the possibility that Enovid might cause thrombotic disorders. Among
the battery of doctors who testified for Searle were Victor A. Drill, who
headed Searle's investigation of Enovid, and Celso-Ramon Garcia, who
performed Searle's Puerto Rico field trials of Enovid. The doctors testi-
* B.A., Cleveland State University; Third-Year student at Cleveland State Univer-
sity, Cleveland-Marshall College of Law.
1 Williams, Harold (M.D., LL.B.), Pregnancy or Dead? The Pill in New Perspective
(New Perspective Publications, 1969). At page 23, Dr. Williams estimates that the
wholesale value of domestic sales of the Pill is presently $100,000,000 per year, and
export sales are equal to that or more.
2 G. D. Searle & Co., Syntex Laboratories, Inc., Mead Johnson Co., Ortho Pharma-
ceutical Co., Parke, Davis & Co., Eli Lilly and Co., The Upjohn Co., and Wyeth
Laboratories, Inc.
3 Seaman, Barbara, The Doctors' Case Against the Pill (Peter H. Wyden, Inc.,
1969).
4 On January 13, 1970, Senator Gaylord Nelson's Small Business Monopoly Sub-
committee began hearings on the safety of oral contraceptives.
5 Letter to author dated January 16, 1970, from Attorney Paul D. Rheingold, Trustee
of Birth Control Pill Group.
6 G. D. Searle & Co. booklet, Planning Your Family (February 2, 1969), bears the
following words on the back cover: "Searle-Where the Pill Began."
7 Federal Food, Drug, and Cosmetic Act § 505(b), 21 U.S.C.A. § 355(b).
8 Circuit Court for County of Kent, Grand Rapids, Michigan, Civil Case No. 1916,
tried May 18-26, 1965.
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fled that they believed plaintiff's condition was caused by her varicose
veins and not by her use of Enovid. The jury agreed, and after a short
deliberation brought back a defendant's verdict.
Black v. Searle9 came to trial on May 12, 1969, and went to the jury
on May 20 on counts of negligence, breach of implied warranty, and
strict liability. This was an action brought by Raymond Black, as ad-
ministrator of the estate of his deceased wife, Elizabeth, who had died
on September 18, 1965, at the age of twenty-nine, from a pulmonary em-
bolism allegedly caused by Enovid. Plaintiff charged that Searle had
failed to adequately warn in its instruction booklets given to doctors,
and, in turn, to patients, that the Pill could cause thromboembolic phe-
nomena (clotting). The issue of warning went to the state of knowledge
chargeable to Searle as of the date of Mrs. Black's death.'0 Plaintiff
maintained that at that time there were approximately 600 reports of
thromboembolic phenomena, including a number of deaths, among wom-
en using Enovid. The plaintiff had a difficult time, however, proving
causation. There were several problems in that regard peculiar to this
case, one being the fact that she had been in a minor automobile acci-
dent about two months prior to her death. Testifying on behalf of the
defendant, Dr. Chris A. Pascuzzi, a pathologist at the South Bend Med-
ical Foundation, stated that the fatal blood clot could have been caused
by either inflammation from an upper respiratory infection or injury to
a vein in the accident. Also testifying for Searle was Dr. Celso-Ramon
Garcia, who stated that in his opinion there was no correlation between
the use of the Pill and thromboembolic phenomena; that the Pill was
safe; that he had no hesitancy about prescribing it for members of his
family; that he had done so in the past and would continue to do so.
Another pro-Pill doctor to testify for Searle was Robert Kistner, a gyne-
cologist from Brookline, Massachusetts, and associated with Harvard's
Medical School. Dr. Kistner testified that he had supervised the use of
Enovid in five to six thousand women and had seen no evidence of
thromboembolic disease. He further stated that he had operated on a
number of these women and found nothing untoward in their pelvic
organs, such as distended veins or evidence of clots. Still another Searle
witness, Dr. Herbert S. Sise, a prolific writer on blood clots, testified that,
in his opinion, there was no relationship between the use of the Pill and
blood clots.
Plaintiff's experts included Dr. Herbert Ratner, Director of the De-
partment of Public Health in Oak Park, Illinois, Dr. Paul E. Haley, a
retired surgeon from South Bend, Indiana, and Dr. John F. Hillabrand,
Director of Obstetrics and Gynecology at St. Vincent's Hospital in To-
9 U. S. Dist. Ct. of Northern District of Indiana-South Bend Division, Civil Case
No. 4082 (1969).
10 Defendant's Tendered Instruction No. 10.
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ledo, Ohio, and chairman of the National Commission of Human Repro-
duction and Rhythm. Dr. Hillabrand testified that, in his opinion, Enovid
was directly connected with Mrs. Black's death. He said that the Pill
slows down circulation of the blood and dilates the veins in the genital
organs and chest so that the blood congeals. He further stated that the
risks attendant with the use of the Pill for contraceptive purposes were
not justified. Dr. Ratner agreed that fatal blood clots can be caused by
the use of Enovid, but that the medical profession had not been given the
objective story on this, so that they were not sure whether there was
such a causal connection. Dr. Haley, who had performed over 400 autop-
sies, testified that he was medically certain that the Pill had a causal
relation to Mrs. Black's death.
From this conflicting testimony emerged a "qualified" defendant's
verdict. The jury found for the defendant on all three counts, but ap-
pended this recommendation to their verdict:
Further, it is the recommendation of this jury that, effective imme-
diately, G. D. Searle & Company, in instruction literature both to
doctors and patients, advise the dangers of the possibility of phle-
bitis, thrombotic, and embolic phenomena."
Judge Robert Grant, however, advised the jury that their added
directive would not be legally binding upon Searle.
Still another case involving thromboembolism was Carmichael v.
Searle, et al.1 2 The plaintiff alleged that she had suffered thromboem-
bolism while taking Enovid. She had, however, discontinued the use of
this contraceptive and had recovered by the time of the trial. Searle used
its perennial witnesses, among whom were Dr. Sise and Dr. Kistner, who
gave their usual pro-Pill testimony. Among plaintiff's witnesses was a
Dr. Samuels, a hematologist, who had done blood studies upon the plain-
tiff to show the change in her blood factors while on and off Enovid. The
jury deliberated for a day and a half, but returned another defendant's
verdict. An appeal has been taken from the decision in this case.
The Manufacturer's Duty
As indicated by the foregoing, plaintiffs did not fare well in the early
Pill litigation. To be sure, there were settlements, 3 but generally for
very low amounts.14 The three theories on which plaintiffs unsuccess-
fully sought recovery were negligence, breach of warranty, and strict
liability.
11 Surface, Bill, "Controversy Over the Pill," Good Housekeeping (Jan., 1970).
12 Superior Court of California for the County of Los Angeles, No. SO C 10586
(1969).
13 The Oct. 4, 1968 edition of Medical World News quotes Searle's president as
saying: "If you can settle for $500.00 instead of $12,000 you do."
14 Supra n. 5.
Sept. 1970
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As regards negligence, when a drug manufacturer develops a new
drug subsequently found to produce harmful side effects, he may be held
liable for negligence where it is shown that he failed to exercise due care
in the development of the drug,15 failed to adequately test the drug,"
or failed to warn of the subsequently-discovered dangerous side effects.
1 7
As an "ethical drug" (one that is available only by prescription), the Pill
is supposed to be advertised and promoted only to physicians.' There-
fore, the drug manufacturer owes a duty to the medical profession to
warn it of dangers inherent in its drugs which, in the exercise of reason-
able care, it knew or should have known, to exist. 19 Moreover, the drug
manufacturer has a further duty to bring home to the prescribing physi-
cian warnings about the potential dangers involved in the use of the
drug.20 The medical profession has a right to rely on a drug company's
representations concerning the safety of its products, so that the "water-
ing down" of warnings by drug manufacturers concerning the safety of
their products is tantamount to inadequate warning.21 Therefore, a drug
manufacturer which discovers harmful side effects produced by its
product, yet fails to give adequate warnings to foreseeable users, is neg-
ligent.22 Further duties imposed on the drug manufacturer include warn-
ing even a small idiosyncratic group of users of the potential dangerous
propensities of its drugs,23 keeping reasonably abreast of scientific knowl-
edge and discoveries in the field,24 and having knowledge of medical jour-
nals which warn of hazardous side effects.
25
Turning now to warranty, recovery has been sought for breach of
the implied warranties of merchantability
2 and fitness for purpose.27
Plaintiffs have contended that a drug which is designed to prevent preg-
nancy, but also causes a side effect such as thrombophlebitis, is neither
fit for a particular purpose nor merchantable. Liability for breach of
these warranties is not based upon fault or failure of the manufacturer
to exercise reasonable care. Merchantability is an implied-in-law repre-
sentation that the thing sold is reasonably fit for the general purpose for
15 Toole v. Richardson-Merrell, Inc., 251 Cal. App. 2d 689, 60 Cal. Rptr. 398 (1967).
16 Roginsky v. Richardson-Merrell, Inc., 378 F. 2d 832 (2d Cir. 1967).
17 Tinnerholm v. Parke Davis & Co., 285 F. Supp. 432 (S.D.N.Y. 1968).
18 Williams, op. cit. supra n. 1, at 80.
19 Tinnerholm v. Parke Davis & Co., supra n. 17.
20 Krug v. Sterling Drug, Inc., et al., 416 S.W. 2d 143 (Mo. Sup. Ct. 1967).
21 Rheingold, Products Liability-The Ethical Drug Manufacturer's Liability, 18 Rut-
gers L. R. 947 (1964).
22 Sterling Drug, Inc. v. Cornish, 370 F. 2d 82 (8th Cir. 1966).
23 Love v. Wolf, 249 Cal. App. 2d 822, 58 Cal. Rptr. 42 (1967).
24 Krug v. Sterling Drug, Inc., et al., supra n. 20.
25 Ibid.
26 Unif. Coml. Code § 2-314.
27 Id. at § 2-315.
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which it is used.2 s The fitness-for-particular-purpose warranty is basi-
cally the same, except that it requires reliance on a particular seller's
skill and judgment. In the case of an ethical drug, the prescribing physi-
cian has been held to be his patient's agent for the special purpose of
receiving statements from the manufacturer concerning the drug.29
Finally, plaintiffs have sought recovery under strict liability in tort.
This theory has been characterized as a "hybrid, having its commence-
ment in contract and its termination in tort," 30 and is said to arise from
the "mere presence of the product on the market." 31 To prevail under
a strict liability theory, the plaintiff must establish the defendant's rela-
tionship to the product, its defective and unreasonably dangerous con-
dition, and a proximate causal connection between the product's danger-
ous condition and the plaintiff's injuries. 32
The Anatomy of a Pill Case
Attorney Paul D. Rheingold 33 is trustee of a seventy-member Birth
Control Pill Group comprised of attorneys with Pill cases who have
banded together to render mutual assistance. Most of the group mem-
bers have one or two cases; a few have a half dozen or more. Mr. Rhein-
gold thinks that many more suits are imminent and will probably be joint
malpractice-product liability actions.34
Such a suit is Charles Gillette, Administrator of the Estate of Alinie
Gillette vs. Samuel L. Friedman, M.D., and G. D. Searle and Company.35
Plaintiff's decedent was twenty-two years old, had two children, and a
history of rheumatic heart disease, anemia, and pulmonary congestion.
She had been using foam as a contraceptive when, in May of 1967, the
defendant doctor started her on Searle's oral contraceptive Ovulen.
During June and July Mrs. Gillette reported migraine headaches, men-
strual frequency and irregularity, and small hair-like veins appearing on
the lower extremities. She was hospitalized on August 27, 1967, and died
two days later. The autopsy showed rheumatic heart disease, bilateral
pulmonary congestion, edema, hemorrhage, and apparent obstruction of
major bronchi.
The defendant doctor was charged with negligence in that he knew,
or should have known, that oral contraceptives should not be prescribed
28 2 Frumer & Friedman, Products Liability § 16.01 (1) (1967).
29 Wechsler v. Hoffman-LaRoche, Inc., 198 Misc. 540, 99 N.Y.S. 2d 588 (1950).
30 Santor v. A & M Karagheusian, Inc., 44 N.J. 52, 207 A. 2d 305 (1965).
31 Id. at 311-12.
32 13 A.L.R. 3d 1066 (1967).
33 Member of the New York City law firm of Speiser, Shumate, Geoghan, Krause &
Rheingold.
34 Supra n. 5.
35 U. S. Dist. Ct. (N.D. Ohio), Case No. C 68-589.
Sept. 1970
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for a patient with the medical history of plaintiff's decedent; that he
assured her that Ovulen was safe; that thereafter he negligently exam-
ined, treated, and advised her and failed to observe and investigate the
cause of certain warning symptoms and continued her on Ovulen until
the date of the last treatment on August 5, 1967.
The defendant Searle was charged with negligence in testing, manu-
facturing, labeling, marketing, and promoting Ovulen; in obtaining writ-
ten permission from the government to market the drug; in failing to
heed warnings which came to it from others about the dangerous prop-
erties of its product; and in failing to make adequate warnings about
these properties to the medical profession and consumers of its products.
Searle was also charged with breach of warranty in that at the time of
the sale it knew or should have known that Ovulen was to be used for
a particular purpose, and it was to be used for human consumption; that
plaintiff's decedent relied on Searle's skill and judgment to select and
furnish safe and suitable drugs; that Ovulen was neither safe nor suit-
able, and directly and proximately resulted in the death of Mrs. Gillette.
As "new drugs" under the provisions of the Federal Food, Drug,
and Cosmetic Act, oral contraceptives must be proved both safe and
effective before permission for commercial distribution is given by the
Food and Drug Administration. 30 This entails the filing by the manu-
facturer of a new drug application, which is accompanied by full reports
of tests made to show the safety of the drug, a full list of its components,
a full statement of its composition, a full description of the methods,
facilities, and controls used for its manufacture, processing, and packing,
and specimens of proposed labeling. 37 Thus, to prove negligence on the
part of the manufacturer in developing and testing the Pill, the plaintiff
must have access to this data. Can the plaintiff obtain this information
to aid him in proving his negligence claim?
The United States District Court for the Eastern District of New
York answered this question affirmatively in Meyer v. Searle,38 an action
arising from plaintiff's sustaining of a coronary artery disease allegedly
caused by Enovid. Plaintiff filed a motion for an order requiring de-
fendant to produce and permit her to inspect and copy correspondence
in defendant's files between it and the Food and Drug Administration
concerning Enovid. The court granted plaintiff's motion, stating that
since the defendant:
. . . controlled the information plaintiff needed, either directly to
sustain her cause of action for negligence, breach of warranty, strict
36 F.D.A. Fact Sheet on Oral Contraceptives (U.S. Dept. of Health, Educ. and Wel-
fare CSS-D 5-7-69).
37 Supra n. 7.
38 41 F.R.D. 290 (E.D.N.Y. 1966).
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liability, and misrepresentation, or indirectly to lead her to useful
and competent evidence, and in view of the nonavailability of the
government's public record wherein a copy of the new drug appli-
cation filed was to be found, good cause existed for discovery.3 9
As regards the failure-to-warn count, the plaintiff must establish
the state of medical knowledge of oral contraceptives as of and prior to
August 29, 1967, the date of his wife's death. In the year 1966, the Index
Medicus, 40 for the first time under its general heading "Oral Contracep-
tives" listed a subheading called "Adverse Effects." Reports of vascular
problems are prominent in this list.4 ' Numerous other medical articles
reporting adverse Pill effects had been published prior to August 29,
1967.42 As early as 1964, the Physician's Desk Reference, the chief source
of drug information that is available to physicians, reported "thrombo-
embolic phenomena with some fatalities" among women on the Pill.
43
Was Searle disseminating information about these side effects to pre-
scribers and/or users of Ovulen? The package insert in the Ovulen-21
Compack4 4 "warns" of the following "adverse effects":
1. Spotting or breakthrough bleeding.
"Such irregular bleeding seldom occurs with Ovulen..
2. Nausea.
"A mild nausea may come and go for several days of the first
cycle or two. The vast majority of women never experience this."
3. Feeling of fullness and weight gain.
"A few women, once they no longer fear pregnancy, feel better
and actually eat more, which, of course, will result in weight
gain."
Searle's final "warning" is: "Unusual changes in your health should
be reported to your physician-just as they should if you were not on
Ovulen."
39 Ibid.
40 Cumulated Index Medicus, Contraceptives, Oral (D5) (1966).
41 Thrombosis of the hepatic veins. "The Budd-Chiara syndrome"-a possible link
between oral contraceptives and thrombosis formation, Ecker, J.A. et al. Amer. J.
Gastrent 45:429-43, June '66; Oral Contraceptives and cerebral arterial occlusion,
Illis., L., et al., Brit. Med. J. 5471:1164-6, 13 Nov. 65; Oral contraceptives, throm-
bosis, and cyclical factors affecting veins, Payne, R.T., Brit. Med. J. 5490:802, 26 Mar.
66; Vascular headaches and oral contraceptives, Trimble, G. X., Canad. Med. Assn.,
J. 94:1241, 4 June 66; Recurring pulmonary embolisms with secondary thrombosis of
the pulmonary arteries due to taking an oral contraceptive, Schweiz Med. Wschr.
95: 1367-72, 9 Oct. 65, etc.
42 A case of multiple arterial thromboses after oral contraceptives and ergotamine,
Brohult, J., et al., Acta Med. Scand. 181:453-6, April, 1967; Liver damage from oral
contraceptives, Stoll, B.A., et al., Brit. Med. J. 5493:960, 16 Apr. 66; Breast problems
and oral contraceptives: a clinical note, Morin, J.E., et al., Conn. Med. 30:569-70, Aug.
66; Oral contraceptives and thromboembolic episodes, Cahal, D.A., Lancet 2:1013, 13
Nov. 65, etc.
43 Williams, op. cit. supra n. 1, at 123.
44 Copyright 1966, "Directions for Use."
Sept. 1970
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Were Searle's detail men "bringing the warning home" to physicians
about the Pill's harmful side effects? Searle's suggested presentation of
Ovulen by detail men to doctors went like this:
Dr.------------------
Searle is happy to present a chemically new, clinically unique oral
contraceptive-OVULEN-offering at the lowest dosage, positive
prevention of pregnancy, with the lowest incidence of side effects-
at the lowest price. The safety of Ovulen has been well established
by world-wide experience including 4 million women's cycles. Ovu-
len has no additional contraindications or precautions to those that
apply to all oral contraceptives. 4
5
As a result of the British studies indicating a seven-to-tenfold in-
crease in fatal and disabling blood clotting diseases among Pill users as
opposed to non-Pill users,46 the Food and Drug Administration directed
that new label warnings for oral contraceptives reflecting these British
findings be required to accompany all packages of oral contraceptives
coming off the production line after June 30, 1968; and that advertise-
ments are to reflect these labeling revisions beginning September 1,
1968.4 7 The uniform labeling must contain the following table on
thromboembolic disease:
Death Rates Hospitalization Rates
Age 20-34 Age 35-44 Age 20-44
Pill Users 1.5/100,000 3.9/100,000 47/100,000
Nonusers 0.2/100,000 0.5/100,000 5/100,000
Four other contraindications were also required to be listed: thrombo-
phlebitis, or history of thrombophlebitis or pulmonary embolism; liver
dysfunction; carcinoma of the breast or genital organs; undiagnosed
vaginal bleeding. Three warnings were required to be given as to when
to discontinue medication. Mentioned are loss of vision or migraine, the
missing of two consecutive periods, and any manifestation or thrombotic
disorders.48
These guidelines are a far cry from the "warnings" being given by
Searle at the time of Mrs. Gillette's death.
Turning back to the theory of strict liability, the chief roadblock to
the argument for strict liability to the drug manufacturer is found in
Comment k to § 402A of the Second Restatement of Torts, which pro-
vides:
45 G. D. Searle & Co. Code 963, June 20, 1966.
46 Inman & Vessey, Investigation of Deaths from Pulmonary, Coronary, and Cere-
bral Thromboembolism and Embolism in Women of Child-bearing Age, L. Brit. Med.
J. 193 (4-27-68); Vessey & Doll, Investigation of Relationship Between Use of Oral
Contraceptives and Thromboembolis Disease, id. at 199.
47 Williams, op. cit. supra n. 1, at 34.
48 Ibid.
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There are some products which, in the present state of human knowl-
edge, are quite incapable of being made safe for their intended and
ordinary use. These are especially common in the field of drugs. An
outstanding example is the vaccine for the Pasteur treatment of
rabies, which not uncommonly leads to very serious and damaging
consequences when it is injected. Since the disease itself invariably
leads to a dreadful death, both the marketing and the use of the vac-
cine are fully justified, notwithstanding the unavoidable degree of
risk which they involve. Such a product, properly prepared and
accompanied by proper directions and warning, is not defective, nor
is it unreasonably dangerous. The same is true of many other drugs,
vaccines, and the like, many of which for this very reason cannot
legally be sold except to physicians, or under the prescription of a
physician. It is also true in particular of many new or experimental
drugs as to which, because of lack of time and opportunity for suffi-
cient medical experience, there can be no assurance of safety, or
perhaps even of purity of ingredients, but such experience as there
is justifies the marketing and use of the drug notwithstanding a
medically recognizable risk. The seller of such products, again with
the qualification that they are properly prepared and marketed, and
proper warning is given, where the situation calls for it, is not to be
held to strict liability for unfortunate consequences attending their
use, merely because he has undertaken to supply the public with an
apparently useful and desirable product, attended with a known but
apparently reasonable risk. (Emphasis added)
The question then to be considered is what constitutes a "defective
condition"? Comment g to § 402A defines it as a "condition not contem-
plated by the ultimate consumer, which will be unreasonably dangerous
to him," and Comment h goes a step further by suggesting that where
a defendant has reason to anticipate a possible danger from a particular
use, and it fails to give adequate warning thereof, a product sold without
such warning is in a defective condition.
The thrust of Comment k seems to be directed at products for which
there is a dire need and no safe alternative available. Do these criteria
apply to the Pill? Can pregnancy be categorized as a "disease which
invariably leads to a dreadful death?" Furthermore, while they may not
be as effective or convenient as the Pill, there is an abundance of other
contraceptive methods available.
49
There is precedent for imposing strict liability on the drug manufac-
turer. In Toole v. Richardson-Merrell, Inc.,5 ° the court said that strict
liability could be imposed on a drug manufacturer for eye injuries in-
curred by plaintiff as a result of the use of defendant's MER/29, where
there was evidence that the manufacturer had been informed of the
49 Planned Parenthood Federation of America, Inc.'s pamphlet "Modem Methods of
Birth Control" (No. 401 - 11-68) recommends seven other effective means of con-
traception.
50 Op. cit. supra n. 15.
Sept. 1970
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dangerous propensities of the drug and yet failed to label the product
with any warnings to that effect.
The reason for joining as a defendant the prescribing physician in
a Pill case is that it is he to whom the duty to warn of the potential ad-
verse effects of the Pill runs. He is then supposed to inform the patient
of these hazards, so that the decision of the patient to still take the Pill
is an "informed consent." With the sword of legal responsibility for Pill
harm hanging over the prescribing physician's head as well as the manu-
facturer's, one insurance company, providing malpractice coverage fur
some 18,000 physicians, sent out on May 14, 1969, the following "Dear
Doctor" letter:
Dear Doctor:
Contraceptive Pills
Because of the increasing awareness of potential complications from
contraceptive pills, and because we are already handling lawsuits
dealing with some of these complications, we are advising physicians
to obtain signed statements from their patients which acknowledge
requests for these pills despite awareness of the serious risks in-
volved.
We offer the enclosed form which can be used in most instances.
Sincerely,
The suggested form:
CONTRACEPTIVE DRUGS
Read Carefully Before Signing!
The prescription for contraceptive drugs on this date and for every
refill hereafter is at my request. In making this request, I am aware
that such drugs can cause serious reactions and complications, both
known and presently unknown.
Date: Signature of patient 51
The Pill's Halo Tarnishes
The great social value of the Pill in this era of the population explo-
sion has been stressed. As the simplest and most effective form of con-
traception available, the Pill has enjoyed a "diplomatic immunity" 52
from criticism. However, in light of the Senate hearings into the Pill
and other reports of its adverse effects,53 the Pill's halo is rapidly tar-
51 Williams, op. cit. supra n. 1, at 95.
52 Seaman, op. cit. supra n. 3, at 239.
53 FDA requires manufacturers of oral contraceptives to revise labeling in light of
British studies linking pills with blood clotting problems, source: New York Times,
May 1, 1968; Health Bulletin, Nov. 9, 1968, Pill-cancer link not ruled out; Committee
on Safety of Drugs in Great Britain says pills with more than 75 micrograms of
estrogen likely to cause blood clotting, source: New York Times, December 14, 1969,
etc.
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nishing. Also ending is the immunity from liability enjoyed by Pill
manufacturers for the past five years.
On April 15, 1970, after a five-week trial, a Brooklyn, New York
jury returned a $250,000.00 plaintiff's verdict in 1Veinert v. Searle.54 Mrs.
Meinert developed a mesenteric thrombosis in 1962 after taking Enovid
for eight months, necessitating an operation to remove portions of her
intestines. Plaintiff proceeded on the bases of express warranty, implied
warranty, strict liability, and common-law negligence; the latter theory
being subdivided into failure to properly test before marketing and fail-
ure to warn of dangers known or which should have been known. The
court rejected the express warranty theory, but submitted the other
three to the jury, along with interrogatories asking the jury to specify
on which theory it made its findings. The jury brought back a verdict
for the plaintiff on all of the three submitted counts.
Lightning struck again on April 24, 1970, when a Federal District
Court jury in Detroit brought back a plaintiff's verdict in Tobin v.
Searle.55 Mrs. Tobin was awarded $225,000.00 (her husband received
$50,000.00 for the loss of her consortium) for clotting in the deep veins
of her right leg following the use of Enovid. Plaintiff was hospitalized
eight times from 1963 through 1965, and underwent surgery twice-once
to sever a nerve in an attempt to end severe pain in-her groin and right
leg, and a second time to replace her destroyed long thigh bone with
artificial tissue. Bolstering plaintiff's case was testimony from plaintiff's
own prescribing physician that he had relied on data sent to him by
Searle, which was incomplete, and some 350 case reports of other clot-
ting incidents obtained from Searle by discovery.
The Future of Pill Litigation
Attorney Paul D. Rheingold believes that there is cause for general
optimism in future Pill cases, but that much depends upon the date of
the use, the notice, the warning, the prescribing physician's role, and the
skill of the individual counsel.56 Mr. Rheingold also feels that Searle
gave neither the Meinert nor the Tobin case an all-out defense, in view
of the abundance of proof now available about the Pill's harmful effects
and the growing number of witnesses who are willing to testify.
Moreover, plaintiffs' attorneys have received judicial sanction for
the sharing of their pre-trial discoveries. In Williams v. Johnson & John-
son,57 the defendant sought a protective order prohibiting plaintiff from
divulging any material obtained from the defendant to any other person.
Judge Tyler denied the motion, explicitly passing upon the objection
54 Supreme Court, Kings County, N. Y. Case No. 2549-65 (1970).
55 U. S. Dist. Ct., Det., Mich., Case No. 25669 (1970).
56 Twelfth Report to the Birth Control Pill Group (May 7, 1970).
57 U. S. Dist. Ct. (S.D.N.Y.), 66 Civ. 3650 (1970).
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made by defendant that a group of lawyers was sharing documents
among themselves. He stated:
Without more, the charging of fees between attorneys collaborating
in similar cases and the collaboration itself both seem reasonable on
their face. There is simply no evidence here that plaintiffs' attorneys
are stirring up litigation. This court will not issue a protective order
when it appears that there is nothing from which to legitimately
protect the movants.
Conclusion
The Pill has been on the market now for ten years and has been in
wide use for five. Only within the last year, however, have widespread
reports of the adverse effects associated with the Pill been publicized.
The Pill has now been associated with maladies that run the gamut from
thrombotic disorders, strokes, cancer, and jaundice on the one hand, to
weight gain, irritability, nausea and depression on the other.58 But, these
problems may be only the exposed part of the iceberg, and proof positive
of what lies beneath may not be established for another ten years.
If the Pill was born from an urgent public policy consideration to
not propagate ourselves off the face of the earth, should not liability for
harm done by it also be grounded on the same consideration? It must be
remembered that the Pill is not a drug which must be taken to control
the ravages of some serious disease. It does not directly alleviate human
suffering, but is taken by normal, healthy women. While the Pill manu-
facturers may be aiding society by providing a convenient and effective
method of checking the overpopulation problem, they are also hand-
somely profiting from Pill sales. Thus, the burden of compensating those
injured by oral contraceptives should properly fall on the manufacturers
and be treated as a cost of production. This, in turn, should prompt the
manufacturers to initiate more ambitious testing and research programs
which may ultimately result in the development of a convenient, effec-
tive, and safe Pill.
58 Seaman, op. cit. supra n. 3.
12https://engagedscholarship.csuohio.edu/clevstlrev/vol19/iss3/13
